{"id":8124,"date":"2026-03-23T15:57:52","date_gmt":"2026-03-23T10:27:52","guid":{"rendered":"https:\/\/lakshmishree.com\/news\/?p=8124"},"modified":"2026-03-23T16:03:43","modified_gmt":"2026-03-23T10:33:43","slug":"details-of-sai-parenterals-limited-ipo","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/news\/details-of-sai-parenterals-limited-ipo\/","title":{"rendered":"Details of Sai Parenteral’s\u00a0Limited IPO : Lot Size, Check Issue Date, Price"},"content":{"rendered":"\n

Sai Parenteral’s<\/strong><\/strong> IPO Price: <\/strong>\u20b9372 to \u20b9392 per share<\/p>\n\n\n\n

IPO Dates:<\/strong> 24th March – 27th March 2026<\/p>\n\n\n\n

\n
\n
\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Company Overview<\/strong><\/h2>\n\n\n\n

Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Business Segments<\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n

The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.<\/p>\n\n\n\n

Product Portfolio<\/h2>\n\n\n\n

The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.<\/p>\n\n\n\n

Market Presence<\/h2>\n\n\n\n

Sai Parenteral’s serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.<\/p>\n\n\n\n

Manufacturing Facilities<\/h2>\n\n\n\n

As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.<\/p>\n\n\n\n

Workforce<\/h2>\n\n\n\n

Sai Parenteral’s serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.<\/p>\n\n\n\n

Competitive Strength<\/h2>\n\n\n\n